GlaxoSmithKline M72/AS01E candidate vaccine gets positive results in Phase 2b clinical trial

tuberculosisis one of the leading causes of infectious disease death worldwideIt is estimated that one quarter of the world's population is infected with latent tuberculosis, in which case mycobacterium tuberculosis is already lurking in the body, only because the body's ongoing immune response to them has caused the patient to show no signs of active TB infectiontoday (September 27), GlaxoSmithKline (GSK) and Aeras announced that GSK's M72/AS01E candidate vaccine has significantly reduced the incidence of tuberculosis in adult stoided HIV-negative latent tuberculosis patients in phase 2b clinicaltrial(2b)the main results of the trial were published in the New England Journal of Medicineabout M72/AS01E
GSKCompany(M72/AS01E candidate vaccine contains M72 recombinant proteins based on two mycobacterium mycobacterium antigens (Mtb32A and Mtb39A), and AS01 immunothetors systemThis immunoading system has been used in GSK's malaria and shingles vaccineThis vaccine stimulates the proliferation of specific lymphocytes and/or the production of interferon-gamma, thus acting as a preventive prevention of tuberculosisthe studya total of 3,573 HIV-negative adult latent TB infection patients were randomized into two groups in this multicenter, randomized double-blind, placebo-controlled Phase 2b clinical trial, receiving either the M72/AS01E vaccine or placebo injections (2 injections, one month apart between each injection)They were then followed for at least two years to see if tuberculosis had developedin the vaccine group, a total of 10 people developed tuberculosis, while in the placebo group, the number of people with tuberculosis was 22 This means that the m72/AS01E vaccine is 54% effective